Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 8/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197356 | 0.95 | CALML3 (0.51) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL14769803 | 0.95 | CALML3 (0.51) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL1393031 | 0.91 | MAOA (0.55) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL13438261 | 0.91 | MAOA (0.55) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL14026522 | 0.91 | MAOA (0.55) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL5742729 | 0.86 | CALML3 (0.43) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL15507021 | 0.81 | MAOA (0.50) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL5172507 | 0.81 | MAOA (0.50) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL10196172 | 0.80 | CALML3 (0.60) | CALML3CYP3A4CYP2C19MAOAMAOB | |
| SCHEMBL5742734 | 0.78 | MAOA (0.55) | CALML3CYP3A4CYP2C19MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | MELINTA SUBSIDIARY CORP. | 2013-03-14 | — | — | US | disclosed |
| US-8324398-B2 | Process for the synthesis of biaryl oxazolidinones | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | PCNA, PGC, SBDS | CALML3 4667/4885CYP3A4 76/4885CYP2C19 161/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CALML3 3842/4885CYP3A4 793/4885CYP2C19 1321/4885 |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | CALML3 4706/4885CYP3A4 62/4885CYP2C19 217/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | CALML3 3842/4885CYP3A4 793/4885CYP2C19 1321/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | CALML3 3842/4885CYP3A4 793/4885CYP2C19 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.